Pleiotropic Effects of Atorvastatin in Heart Failure: Role in Oxidative Stress, Inflammation, Endothelial Function, and Exercise Capacity

Journal of Heart and Lung Transplantation

Volumn 27, Issue 4, 2008, Pages 435-441

  Castro, Pablo F ^a   Miranda, Rodrigo ^a   Verdejo, Hugo E ^a   Greig, Douglas ^a   Gabrielli, Luigi A ^a   Alcaino, Hernán ^b,c   Chiong, Mario ^b,c   Bustos, Carlos ^b   Garcia, Lorena ^b,c   Mellado, Rosemarie ^b,c   Vukasovic, José Luis ^d   Godoy, Ivan ^a   Lavandero, Sergio ^b,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d HOSPITAL DEL SALVADOR   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CREATINE KINASE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE B; INTERLEUKIN 6; MALONALDEHYDE; PLACEBO; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG WITHDRAWAL; EXERCISE; FEMALE; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; MALE; MYALGIA; MYOCARDITIS; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RABDOMYOLYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC HEART FAILURE; TREATMENT DURATION;

AGED; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; PYRROLES; TIME FACTORS; VASODILATION; WALKING;

EID: 40949135645     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.01.012     Document Type: Article

References (40)

1. Grieve D.J., and Shah A.M. Oxidative stress in heart failure. More than just damage. Eur Heart J 24 (2003) 2161-2163
2. Thomas N.J. Myocardial protection of the donor heart and the avoidance of oxidative stress. J Heart Lung Transplant 24 (2005) 1995-1996
3. Castro P.F., Díaz-Araya G., Nettle D., et al. Effects of early decrease in oxidative stress after medical therapy in patients with class IV congestive heart failure. Am J Cardiol 89 (2002) 236-239
4. Heistad D.D. Oxidative stress and vascular disease: 2005 Duff lecture. Arterioscler Thromb Vasc Biol 26 (2006) 689-695
5. Sharma R., and Davidoff M.N. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 8 (2002) 165-172
6. Conraads V.M., Bosmans J.M., Schuerwegh A.J., et al. Effect of short-term treatment with pravastatin on cytokines and cytokine receptors in patients with chronic heart failure due to ischemic and nonischemic disease. J Heart Lung Transplant 24 (2005) 1114-1117
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
8. Nakagami H., Jensen K.S., and Liao J.K. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 35 (2003) 398-403
9. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47 (2000) 648-657
10. Node K., Fujita M., Kitakaze M., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
11. Castro P.F., Greig D., Pérez O., et al. Relation between oxidative stress, catecholamines, and impaired chronotropic response to exercise in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92 (2003) 215-218
12. Landmesser U., Spiekermann S., Dikalov S., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106 (2002) 3073-3078
13. Misra H.P., and Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247 (1972) 3170-3177
14. Manenti L., Paganoni P., Floriani I., et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 39 (2003) 1948-1956
15. Oliver G.W., Leferson J.D., Stetler-Stevenson W.G., et al. Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal Biochem 244 (1997) 161-166
16. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-Invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 202;360:7-22.
18. Cannon C.P., Braunwald E., McCabe C.H., et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction. N Engl J Med 350 (2004) 1495-1504
19. Waters D.D., Guyton J.R., Herington D.M., et al., TNT Steering Committee and Investigators. Treating to New Targets (TNT) Study: Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 (2004) 154-158
20. Horwich T.B., Hamilton M.A., Maclellan W.R., et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
21. Sakatani T., Shirayama T., Suzaki Y., et al. The association between cholesterol and mortality in heart failure. Comparison between patients with and without coronary artery disease. Int Heart J 46 (2005) 619-629
22. Wojnicz R., Wilczek K., Nowalany-Kozielska E., et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97 (2006) 899-904
23. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
24. Folkeringa R.J., Van Kraaij D.J., Tieleman R.G., et al. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 12 (2006) 134-138
25. Mozaffarian D., Nye R., and Levy W.C. Statins therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 (2004) 1124-1129
26. Mitchell L.B., Powell J.L., Gillis A.M., et al., AVID Investigators. Are lipid lowering drugs also antiarrythmic drugs?. An analysis of the Antiarrythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
27. Dickinson M.G., Ip J.H., Olshansky B., et al., SCD-HeFT Investigators. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 153 (2007) 573-578
28. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Eng J Med 357 (2007) 2248-2261
29. Landmesser U., Bahlmann F., Mueller M., et al. Simvastatin versus ezetimibe. Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
30. Abrams J. C-reactive protein, inflammation, and coronary risk: an update. Cardiol Clin 21 (2003) 327-331
31. Paulus W.J. Cytokines and heart failure. Heart Fail Monit 1 (2000) 50-56
32. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methylglutharyl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
33. Ichihara S., Noda A., Nagata K., et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 69 (2006) 726-735
34. Nakaya R., Uzui H., Shimizu H., et al. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 105 (2005) 67-73
35. Reinhardt D., Sigusch H.H., Hensse J., et al. Cardiac remodeling in end stage failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (2002) 525-530
36. Altieri P., Brunelli C., Garibaldi S., et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33 (2003) 648-656
37. Yan A.T., Yan R.T., Spinale F.G., et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12 (2006) 514-519
38. Deschamps A.M., and Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 69 (2006) 666-676
39. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6 (1990) 121-125
40. Lalu M.M., Pasini E., Schulze C.J., et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur J Heart 26 (2005) 27-35